165 results
8-K
EX-99.1
VXRT
Vaxart Inc
13 May 24
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
4:03pm
facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials
8-K
EX-99.1
VXRT
Vaxart Inc
30 Apr 24
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
4:22pm
substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy
8-K
EX-99.1
vdaiz8 m4qysvtyti8w3
14 Mar 24
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
4:05pm
8-K
EX-99.1
u3wqi 8bl
6 Mar 24
Vaxart, Inc. Appoints Steven Lo as New President, Chief Executive Officer, and Director
9:23am
8-K
EX-99.1
8x1iby
19 Jan 24
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
5:14pm
8-K
EX-99.1
0kd skx4s
16 Jan 24
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
5:18pm
8-K
EX-99.1
2itwtp m8w
16 Jan 24
Vaxart, Inc. Announces Management Change
9:19am
8-K
EX-99.1
fy35o
2 Nov 23
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
549v 0zd9yku4
6 Sep 23
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
4:43pm
8-K
EX-99.1
yknlfda0 zvcd
3 Aug 23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
4:20pm
8-K
EX-99.1
m33al14g1e5j
10 Jul 23
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
4:12pm
DEFA14A
1h5k3p29tz
21 Jun 23
Additional proxy soliciting materials
5:18pm
8-K
EX-99.1
5snxh m8do1bjkh2d
8 Jun 23
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
4:27pm